Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
1 clinical trials · Condition
◉ Watch Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
| Record | Firm | Date |
|---|---|---|
| Individual Patient Compassionate Use of Mirdametinib (NCT05028166) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany |
Track Neurofibromatosis Type 1-Associated Plexiform Neurofibromas automatically
Every clearance here is in the API, with alerts when new ones post.